Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model

被引:20
作者
Liu, Rui [1 ,2 ]
Zheng, Honggang [1 ,2 ]
Li, Weidong [1 ,2 ]
Guo, Qiujun [1 ,2 ,3 ]
He, Shulin [1 ,3 ]
Hirasaki, Yoshiro [1 ,4 ]
Hou, Wei [1 ,2 ]
Hua, Baojin [1 ,2 ]
Li, Conghuang [1 ,2 ]
Bao, Yanju [1 ,2 ]
Gao, Yebo [1 ,2 ,3 ]
Qi, Xin [1 ,2 ]
Pei, Yingxia [1 ,2 ]
Zhang, Yun [1 ,2 ]
机构
[1] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Oncol, Beijing 100053, Peoples R China
[2] China Acad Chinese Med Sci, Inst Canc, Beijing 100053, Peoples R China
[3] Beijing Univ Chinese Med, Beijing 100029, Peoples R China
[4] Chiba Univ, Grad Sch Med, Dept Japanese Oriental Kampo Med, Chuo Ku, Chiba 2608670, Japan
基金
中国国家自然科学基金;
关键词
Lung cancer; Fei-Liu-Ping ointment; Celecoxib; Inflammatory microenvironment; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER CELL-LINES; TUMOR MICROENVIRONMENT; MATRIX METALLOPROTEINASES; INHIBITOR CELECOXIB; PHASE-II; MAINTENANCE TREATMENT; COX-2; GROWTH; TARGET;
D O I
10.1186/s12967-015-0728-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Fei-Liu-Ping (FLP) ointment is an oral prescription medication that has been widely applied to treat lung cancer patients in China. Regulation of the metastatic microenvironment is an important therapeutic approach for prevention and treatment of tumor recurrence and metastasis. The advantage of Traditional Chinese Medicine management of lung cancer lies in the prevention of recurrence and metastasis. Our previous study has demonstrated that FLP ointment could regulate lung inflammatory microenvironment in vitro. However, the effects of FLP on the tumor microenvironment in vivo are still poorly understood. The objective of this study is to investigate the effect of FLP alone or in combination with celecoxib in the prevention of lung cancer progression by Cyclooxygenase (Cox)-2 mediated tumor inflammatory microenvironment in vivo. Methods: 120 Lewis lung carcinoma xenograft mice were divided equally into four groups: vehicle, FLP, celecoxib, and FLP plus celecoxib. The dynamic growth of the xenografted tumors was observed using an in vivo fluorescence imaging system. Mice were sacrificed on day 14, day 21, and day 28, and tumor specimens and lung tissues were harvested to detect the metastasis-associated protein expression. Results: Tumor inhibition rate was 15.4, 44.2, 47.4 % at day 14, 37.3, 34.7, 61.5 % at day 21, and 15.5, 10.3, 32.5 % at day 28 after treatment of FLP, celecoxib, and FLP plus celecoxib, respectively. Upon treatment of FLP and celecoxib together, lung metastasis rate was 30 % (8 metastatic nodules) lower than other groups. FLP inhibited Cox-2 expression in a time-dependent manner. Moreover, FLP inhibited N-cadherin, matrix metalloproteinases (MMP)-9, and Vimentin expression. Treatment of FLP in combination with celecoxib was more effective than FLP or celecoxib alone in inhibiting vascular endothelial growth factor, platelet-derived growth factor receptors beta, microsomal Prostaglandin E synthase-1, MMP-2, MMP-9, N-cadherin, and Vimentin expression, but increased E-cadherin expression. Conclusions: FLP inhibited tumor growth and metastasis in a Lewis lung xenograft mice model through the Cox-2 pathway. FLP in combination with celecoxib enhanced the antitumor growth and anti-metastasis effects. Traditional Chinese herbs combined with anti-inflammatory drugs might offer a promising strategy to prevent tumor metastasis.
引用
收藏
页数:14
相关论文
共 58 条
  • [1] Gefitinib plus celecoxilb in chernotherapy-naive patients with stage IIIB/IV non-small cell lung cancer - A phase II study from the Hoosier Oncology Group
    Agarwala, Anuj
    Fisher, William
    Bruetman, Daniel
    McClean, John
    Taber, David
    Titzer, Michael
    Juliar, Beth
    Yu, Menggang
    Breen, Tim
    Einhorn, Lawrence H.
    Hanna, Nasser
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 374 - 379
  • [2] [Anonymous], 2013, CANC FACTS FIG 2013
  • [3] [Anonymous], J TRADIT CHIN MED
  • [4] Phase II Study of Celecoxib with Cisplatin Plus Etoposide in Extensive-Stage Small Cell Lung Cancer
    Araujo, Antonio M. F.
    Mendez, Jose C.
    Coelho, Ana L.
    Sousa, Berta
    Barata, Fernando
    Figueiredo, Ana
    Amaro, Teresina
    Azevedo, Isabel
    Soares, Marta
    [J]. CANCER INVESTIGATION, 2009, 27 (04) : 391 - 396
  • [5] Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer
    Argiris, A
    Kut, V
    Luong, L
    Avram, MJ
    [J]. INVESTIGATIONAL NEW DRUGS, 2006, 24 (03) : 203 - 212
  • [6] Cancer-Related Inflammation
    Candido, Juliana
    Hagemann, Thorsten
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 : S79 - S84
  • [7] Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis
    Curran, S
    Murray, GI
    [J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (13) : 1621 - 1630
  • [8] de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969
  • [9] Matrix metalloproteinases and tumor metastasis
    Deryugina, EI
    Quigley, JP
    [J]. CANCER AND METASTASIS REVIEWS, 2006, 25 (01) : 9 - 34
  • [10] Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy A NICE Single Technology Appraisal
    Dickson, Rumona
    Bagust, Adrian
    Boland, Angela
    Blundell, Michaela
    Davis, Helen
    Dundar, Yenal
    Hockenhull, Juliet
    Saborido, Carlos Martin
    Oyee, James
    Ramani, Vidhya Sagar
    [J]. PHARMACOECONOMICS, 2011, 29 (12) : 1051 - 1062